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Abstract: Background: The respiratory system is one of the main entrance gates for infection. The
aim of this work was to compare the appearance of specific mucosal pro-inflammatory and common
anti-microbial defence factors in healthy lung tissue, from an ontogenetic point of view. Materials and
methods: Healthy lung tissues were collected from 15 patients (three females and 12 males) in the
age range from 18 to 86. Immunohistochemistry to human β defensin 2 (HBD-2), human β defensin
3 (HBD-3), human β defensin 4 (HBD-4), cathelicidine (LL-37) and interleukine 17A (IL-17A) were
performed. Results: The lung tissue material contained bronchial and lung parenchyma material
in which no histological changes, connected with the inflammatory process, were detected. During
the study, various statistically significant differences were detected in immunoreactive expression
between different factors in all lung tissue structures. Conclusion: All healthy lung structures, but
especially the cartilage, alveolar epithelium and the alveolar macrophages, are the main locations for
the baseline synthesis of antimicrobial proteins and IL-17A. Cartilage shows high functional plasticity
of this structure, including significant antimicrobial activity and participation in local lung protection
response. Interrelated changes between antimicrobial proteins in different tissue confirm baseline
synergistical cooperation of all these factors in healthy lung host defence.
Keywords: healthy lungs; factors; immunity; respiratory system; local defence
1. Introduction
The respiratory system is one of the main entrance gates for infection, so it is important
for the organism to complement it with several innate host defence components. It is
necessary to protect the organism from pathogen penetration, that is why the respiratory
system is equipped with different protection mechanisms. Lungs have a huge surface and
at the same time the alveolar epithelium is very thin and delicate, in order to be able to
provide the exchange of oxygen and carbon dioxide [1]. Such a structure increases risk of
developing an infection in the lungs and spreading the infection throughout the whole
organism. Intact epithelium with mucociliary clearance, antimicrobial activity of the airway
surface fluid, opsonization with surfactant protein and bactericidal activity of the alveolar
macrophages are necessary to prevent penetration of particles and infection agents through
the upper respiratory system and to prevent induction of inflammation in the lungs [2].
Mutual cooperation of different immune factors allows for stronger immune response and
protection of the organism against pathogens.
Antimicrobial peptides (AMPs) comprise a large family of effector molecules of the
innate immune defence. Two families of AMPs, defensins and cathelicidines, are the
main antimicrobial molecules in the respiratory system defence [3]. The main attention
in antimicrobial activity in the respiratory system is attracted by such members of human
beta defensin family as human beta defensin 2 (HBD-2), human beta defensin 3 (HBD-3)
and human beta defensin 4 (HBD-4). The cathelicidine family includes only one human
cathelicidine—LL-37—whereby antimicrobial activity is one of its many functions.
Defensins are small, cationic antimicrobial polypeptides and take part in immune
host defence, acting as innate and adaptive immunity mediators against bacteria, fungi,
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viruses and parasites [4]. HBD-2 is encoded by defensin beta 4 (DEFB4) gene, which
is stimulated by a wide spectrum of immune cells, such as monocytes, macrophages,
granulocytes and so on, but the main source of the HBD-2 is the epithelium [5–7]. Relevant
studies demonstrated that tumour necrosis factor α (TNF-α), interleukin 1β (IL-1β), IL-22,
extracellular Ca2+ and lipopolysaccharides (LPS) are elicited in HBD-2 mRNA induction
through Toll-Like receptors (TLRs), dependent phosphoinositide 3-kinase (PI3K), nuclear
factor-kappa B (NFkB) and mitogen-activated protein kinase (MAPK) pathways [4,8–11]. It
demonstrates the large number of possibilities for mobilizing HBD-2, supporting the theory
of its importance and superiority as an antimicrobial peptide. It is important to mention
that HBD-2 is expressed in low doses in healthy lung tissues and is retained in surfactant to
protect the respiratory system by direct destruction of pathogens or synergistic work with
other antimicrobial molecules (lactoferrin) [12]. It is interesting to note that Gram-negative
bacteria-induced HBD-2 mobilization is higher compared to the same situation with Gram-
positive bacteria. It can be concluded that HBD-2 is able to fully destroy Pseudomonas
aeruginosa, but not Staphylococcus aureus [13]. Main action of HBD-2 is broad spectrum
antimicrobial activity mainly with anti-inflammatory activity. HBD-2 has the ability to
suppress inflammatory process in lungs by decreasing IL-9, IL-13, IL-1β, IL-6 and TNF-α
and, also, HBD-2 increases anti-inflammatory mediator IL-10 expression and improves
pulmonary function [14,15]. HBD-2 chemoattracting abilities induce dendritic cell and T
cell migration through C-C chemokine receptor type 6 (CCR6) [16]. Varied ways of HBD-2
activation, HBD-2 high expression in the epithelium and other tissues, variable functions
and high activity in host defence prove antimicrobial peptide importance in respiratory
host defence.
HBD-3 is encoded by DEFB103 gene, and its activity has been detected primarily in
epithelial cells of the respiratory tract and genitourinary tract [17,18]. Induction of the
HBD-3 gene is mediated by TNF-α, interferon γ (INF-γ), IL-1, lipopolysaccharides (LPS)
and other factors, through specific Toll-Like receptors (TLR2/5/9) that leads to NFkB and
MAPK pathway activation [19]. As all defensins, HBD-3 has pro- and anti-inflammatory
activity. In contrast to HBD-2, HBD-3 shows significant activity towards Staphylococcus
aureus and it is a more potent antimicrobial peptide against Gram-positive bacteria in the
respiratory tract [18]. Furthermore, salt sensitivity, which was observed in HBD-2 and
HBD-4, has not been detected in HBD-3 [20], this demonstrates the increased ability of the
mediator to adapt and remain active during significant environmental changes. HBD-3,
the same as HBD-2, can mobilize dendritic cells and memory T cells trough CCR6 [21].
Furthermore, it has been detected that it stimulates monocyte migration and activation
trough CCR2 for macrophage recruitment [22].
HBD-4 are small cationic peptides whose expression was observed in epithelial cells
and neutrophils [23]. Despite HBD-4 high expression in the epithelium of the testis and the
gastric antrum, HBD-4 was also detected in lungs, but in a smaller amount [24]. HBD-4 gene
expression is upregulated by endogenous (TNF-α, IL-1β, Ca2+ and phorbol 12-myristate
13-acetate (PMA)) and exogenous (LPS) factors [25]. It is important to mention, that
HBD-4 activity against Pseudomonas aeruginosa is stronger than the activity of any other
β-defensin [24]. HBD-4 has direct antimicrobial activity and is involved in cytokine and
chemokine production such as IL-10, IL-6, INF-γ, IP-10 and others [22]. Interesting to
mention that collaboration of HBD-4 with other antimicrobial peptides like HBD-3 and
lysozyme was observed that induce mast cell migration, degranulation, prostaglandin D2
(PGD2) generation and chemotaxis [26,27]. HBD-4 has been identified in cartilage and
showed weak expression in healthy tissues [28].
Every defensin has its own dominant function in host defence, but their fulfilling
activity of each other (HBD-3 activity against Gram-negative bacteria is stronger than
HBD-2 activity) and synergistic behaviour (HBD-3 and HBD-4 together stimulate mast cell
migration) provide the highest antimicrobial activity.
Human cathelicidine (LL-37) is encoded by the cathelicidine antimicrobial peptide
(CAMP) gene and has a broad-spectrum of antimicrobial activity against Gram-positive and
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Gram-negative bacteria, viruses, fungi and protozoa [29,30]. LL-37 is produced by mucosal
epithelial cells, keratinocytes, adipocytes and immune cells [1,31]. Furthermore, it has
been observed that vitamin D or calcitriol significantly induces expression of cathelicidine
mRNA and synthesis of intracellular human cationic antimicrobial peptide (hCAP-18) pro-
peptide form [32]. The expression of hCAP-18 and its transformation to the antimicrobial
active form is induced by proinflammatory cytokines, growth factors, by other endogenous
factors, and by exogenous factors like LPS [31,33]. LL-37 has two major functions in host
defence. The first one is direct inhibition of pathogens. LL-37 recruit neutrophils, monocytes
and T cells by connecting to formyl peptide receptor-like 1 (FPRL-1) and glyceraldehyde
3-phosphate dehydrogenase (GAPDH) [1,34]. The second one is modulation of innate
and adaptive immune responses. LL-37 activate macrophages through epidermal growth
factor receptor (EGFR) and inhibit their response to LPS [1,34]. LL-37 anti-inflammatory
activity is expressed as IL-1β, IL-6, IL-8 and TNF-α production reduction through TLR2
and TLR4 [35].
Although, antimicrobial peptides are the main members of respiratory system immune
defence, some other mediators are involved in stimulation of AMPs secretion and even
in synergistic cooperation with these antimicrobial peptides. One of these mediators is
interleukin 17A (IL-17A), which is involved in antimicrobial peptide gene regulation and
cooperation with them.
IL-17A is a member of the big proinflammatory mediator family and it is important
for host defence at mucosal surfaces. The main source of IL-17 was detected to be CD4+ T
helpers, which became known as “Th17 cells”, but its production is also mediated by other
immune cells such as natural killer cells, γδ-T cells, type 3 innate lymphoid cells (ILC3),
neutrophils and macrophages [36–38]. Its powerful induction of inflammation is due to
synergistical activity with other stimuli by stabilization of target mRNA [20,39]. During
the acute lung inflammatory process, IL-17A induced gene stabilization and mediator
production and lead to the mobilization of phagocytes and production of antimicrobial
peptides [37,40]. One of these peptides is HBD-2, whose expression is regulated by IL-17A
through JAK/NFkB pathway [41]. Interestingly, LL-37 also induces IL-17A expression.
Moreover, long activation of IL-17A by LL-37 and cooperation of these two mediators, pro-
long and enhance the main inflammatory processes in tissues [42]. Overall, the synergy of
LL-37 and IL-17A, HBD-3 and HBD-4 supports the hypothesis that synergistic cooperation
of different immune factors can lead to a higher response to pathogens and faster reduction
of inflammation.
According to the above-mentioned, the aim of this work was to compare the appear-
ance of specific mucosal pro-inflammatory and common anti-microbial defence factors in
healthy lung tissue, from an ontogenetic point of view.
2. Materials and Methods
2.1. Material Characteristics of Subjects
This study was approved by the Ethics Committee for Clinical Research of Medicine
and Pharmaceutical Products at Pauls Stradins Clinical University Hospital Development
Foundation in Latvia (Nr. 230113-17L, 2013). The study was conducted at the Institute
of Anatomy and Anthropology, Latvia. All of the patients gave their informed written
consent to participate in the study. The respiratory system material was obtained from
15 patients, 12 of them being males in the age range from 19–86 years and 3 of them females
in the age range from 18 to 59 years. Tissues were not associated with inflammation or
any other pathology. The material was collected during postmortem autopsy from persons
who died in an accident and not from respiratory tract disease or during lung operation.
Tissue material was collected from Pauls Stradins Clinical University hospital and Riga
Stradins University Anatomy and Anthropology institute archive (lung tissue material)
collection. The autopsy material contained bronchial wall tissue including cartilage from
main and lobar bronchi, and lung parenchymal tissue. The lung tissue material used in the
study was obtained at autopsy 12–24 h after the biological death of patients.
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For patient selection, to exclude as many co-factors and confounders as possible,
inclusion and exclusion criteria were developed.
Inclusion criteria: (1) A patient older than seven years (age when the lungs are
considered morphologically mature and corresponding to the lung morphology of an
adult individuals); (2) the obtained lung tissue sample histologically complies with the
requirements of the tissue sample determined in the study and contains bronchial material
(and/or lung parenchymal material).
Exclusion criteria: (1) Pathological finding in the lung tissue material (inflammatory
cell infiltration, chronic inflammation, etc.); (2) acute or chronic lung disease in medical
history; (3) lung oncological disease; (4) no bronchial and/or pulmonary material is found
in the tissue section. The causes of death were accidents or fatal self-harm (trauma to
body parts and organs, suicides that were not compatible with life). The causes of death
of 6 individuals were associated with acute cardiovascular failure and/or ischemic heart
disease (cause of death—cardiac arrest).
2.2. Immunohistochemical Analysis
The tissue specimens were fixed in a mixture of 2% formaldehyde and 0.2% picric
acid in 0.1 M phosphate buffer (pH 7.2). Afterwards, they were rinsed in Tyrode buffer
containing 10% saccharose for 12 h, then embedded into paraffin and cut into 3–4 µm thin
sections. Biotin-Streptavidin biochemical method was used for immunohistochemistry
(IMH) to detect: LL-37 (orb88370, working dilution 1:100, Biorbyt Limited, Cambridge,
UK); HBD-4 (ab14419, working dilution 1:200, Abcam, San Francisco, CA, USA); HBD-3
(rb183268, working dilution 1:100, Biorbyt Limited, Cambridge, UK); HBD-2 (sc-20798,
working dilution 1:100, Santa Cruz Biotechnology, Inc., Dallas, TX, USA); IL-17A (orb48920,
working dilution 1:200, Biorbyt Limited, Cambridge, UK).
The stained slides were analysed by light microscopy (Leica RM2245, Leica Biosys-
tems Richmond Inc., Richmond, Buffalo Grove, IL, USA) using nonparametric evaluation.
The results were evaluated by grading the appearance of the positively stained cells in
the visual field [43]. The designation was as follows: 0—no positive structures in the
visual field; 0/+—occasional positive structures in the visual field; +—a few positive
structures; +/++—a few to a moderate number of positive structures in the visual field;
++—a moderate number of positive structures in the visual field; ++/+++—moderate to
numerous positive structures in the visual field; +++—numerous positive structures with
the visual field; +++/++++—numerous to abundant positive structures in the visual field;
++++—abundant positive structures in the visual field.
For visual illustration, a Leica DM500RB digital camera (Leica Biosystems Rich-
mond Inc., Richmond, Buffalo Grove, IL, USA) and Microsoft Photo editor (version
2021.21070.22007.0, Microsoft Corporation, Redmond, WA, USA) were used.
2.3. Statistical Analysis
Statistical data were ranked as ordinal values, where no positive structures (0) in the
visual field were ranked with the value of 0, occasional positive structures (0/+) in the
visual field were ranked with the value of 1, few positive structures (+) were ranked with
the value of 2, a few to a moderate number of positive structures (+/++) were ranked
with the value of 3, a moderate number of positive structures (++) in the visual field were
ranked with the value of 4, moderate to numerous positive structures (++/+++) were
ranked with the value of 5, numerous positive structures (+++) were ranked with the value
of 6, numerous to abundant positive structures (+++/++++) were ranked with the value of
7 and abundant positive structures (++++) were ranked with the value of 8.
We used the non-parametric Wilcoxon test to compare the different mediator expres-
sion in the same structure and Spearman’s rank correlation coefficient (ρ), where ρ = 0–0.19
was assumed as a very weak correlation, ρ = 0.2–0.39 was assumed as a weak correlation,
ρ = 0.4–0.59 was assumed as a moderate correlation, ρ = 0.6–0.79 was assumed as a strong
correlation and ρ = 0.8–1 was assumed as a very strong correlation.
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The statistical data processing was performed with IBM SPSS (Statistical Package for
the Social Sciences) version 26.0 (IBM company, North Castle, Armonk, NY, USA). The
significance level for all tests was selected as a p-value < 0.05 (5%).
3. Results
3.1. Tissue Review
The lung tissue material contained bronchial and lung parenchyma material in which
no histological changes connected with inflammatory process were detected.
3.2. Immunohistochemical (IMH) Data
The highest expression of HBD-2 was observed in cartilage where mainly a moderate
number of positive structures was detected (Table 1, Figure 1). HBD-2 was present in a few to
moderate number of alveolar macrophages and alveolar epithelium (Table 1), A few positive
structures of HBD-2 appeared in connective tissue and bronchial epithelium (Table 1, Figure 1).
Glands demonstrated only occasional number of positive HBD-2 cells (Table 1).
Table 1. Relative number of HBD-2 and HBD-3-positive structures in the healthy lung structures: cartilage, connective
tissue, glands, bronchial epithelium, alveolar macrophages and alveolar epithelium.
Nr Age
HBD-2 HBD-3
C CT G BE AE AM C CT G BE AE AM
1 18 +++ + + + 0 0 ++ + +/++ +/++ 0 0
2 19 +++ +/++ +/++ ++ 0 0 +/++ + ++ + 0 0
3 19 ++ 0 0 + + + ++ + 0/+ 0/+ +/++ +
4 25 +++ +/++ ++ 0 +/++ +/++ +++ +/++ + ++ +/++ +
5 27 ++ ++ + 0/+ +/++ ++ ++ 0/+ + + ++ ++
6 29 ++/+++ 0/+ 0/+ 0 +++ ++ ++ 0/+ 0/+ 0 ++/+++ ++/+++
7 33 ++ ++ 0/+ 0 ++ + ++ 0/+ 0 0 ++ ++
8 35 +/++ +/++ 0/+ 0 + + + +/++ 0/+ 0/+ +/++ 0/+
9 38 ++/+++ 0/+ 0 0/+ +/++ ++ ++ 0 + +/++ +/++ +
10 45 ++ 0 0/+ + ++ ++ +/++ + + + ++ +/++
11 55 + + 0 0 +/++ ++/+++ + 0/+ 0/+ + ++ +/++
12 56 ++ +/++ 0/+ + +/++ ++ +/++ + 0/+ + +/++ 0/+
13 59 +++ + 0 0/+ +/++ 0/+ ++ 0 0 0/+ ++ +
14 74 ++ 0 + 0 ++ ++ +/++ 0/+ 0/+ 0 ++ +/++
15 86 +/++ 0/+ 0/+ 0 +/++ ++ +/++ 0 0/+ 0 +/++ +
Common ++ + 0/+ + +/++ +/++ ++ + + + ++ +/++
Abbreviations: C, cartilage; CT, connective tissue, G, glands; BE, bronchial epithelium; AE, alveolar epithelium; AM, alveolar macrophages;
HBD-2, human β defensin 2; HBD-3, human β defensin 3; 0—no positive structures in the visual field; 0/+—occasional positive structures
in the visual field; +—few positive structures; +/++—few to moderate number of positive structures in the visual field; ++—moderate
number of positive structures in the visual field; ++/+++—moderate to numerous positive structures in the visual field; +++—numerous
positive structures with the visual field.




Figure 1. Note a moderate number of HBD-2 positive cells in the bronchial epithelium and carti-
lage of 59-year-old female bronchial wall. HBD-2 IMH, ×250. 
 
Figure 2. Note a few HBD-3 positive cells in the bronchial and alveolar epithelium, and in connec-
tive tissue of 59-year-old female bronchial wall. HBD-3 IMH, ×200. 
The highest expression of HBD-4 was observed in cartilage of bronchial wall (mod-
erate) (Table 2, Figure 3). A few to moderate HBD-4 expression was detected in alveolar 
epithelium and alveolar macrophages (Table 2, Figure 3). Occasional expression of HBD-
4 was detected in connective tissue, glands and bronchial epithelium (Table 2, Figure 3). 
Table 2. Relative number of HBD-4-positive structures in the healthy lung structures: cartilage, 
connective tissue, glands, bronchial epithelium, alveolar macrophages and alveolar epithelium. 
Nr Age 
HBD-4 
C CT G BE AE AM 
1 18 +/++ 0 0/+ + 0 0 
2 19 ++ + ++ ++ 0 0 
3 19 +/++ 0/+ 0/+ 0/+ + + 
4 25 ++/+++ ++ 0/+ 0/+ +++ ++ 
5 27 ++ 0/+ 0 0 +/++ 0/+ 
6 29 ++ + 0/+ 0 ++ +++ 
7 33 +/++ 0/+ 0 0 ++ ++ 
8 35 +/++ 0 0 0 +/++ + 
Figure 1. Note a moderate number of HBD-2 positive cells in the bronchial epithelium and cartilage
of 59-year-old female bronchial wall. HBD-2 IMH, ×250.
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Upon viewing HBD-3 in cartilage and alveolar epithelium, a moderate number of
factor positive structures were detected in these locations (Table 1, Figure 2). A few to
moderate HBD-3 positive structures were detected in alveolar macrophages (Table 1).
Furthermore, glands, connective tissue and bronchial epithelium demonstrated only few
positive cells (Table 1, Figure 2).
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The highest expression of HBD-4 was observed in cartilage of bronchial wall (mod-
erate) (Table 2, Figure 3). A few to moderate HBD-4 expression was detected in alveolar 
epithelium and alveolar macrophages (Table 2, Figure 3). Occasional expression of HBD-
4 was detected in connective tissue, glands and bronchial epithelium (Table 2, Figure 3). 
Table 2. Relative number of HBD-4-positive structures in the healthy lung structures: cartilage, 
connective tissue, glands, bronchial epithelium, alveolar macrophages and alveolar epithelium. 
Nr Age 
HBD-4 
C CT G BE AE AM 
1 18 +/++ 0 0/+ + 0 0 
2 19 ++ + ++ ++ 0 0 
3 19 +/++ 0/+ 0/+ 0/+ + + 
4 25 ++/+++ ++ 0/+ 0/+ +++ ++ 
5 27 ++ 0/+ 0 0 +/++ 0/+ 
6 29 ++ + 0/+ 0 ++ +++ 
7 33 +/++ 0/+ 0 0 ++ ++ 
8 35 +/++ 0 0 0 +/++ + 
Figure 2. ote a few HBD-3 positive cells in the bronchial and alveolar epithelium, and in connective
tissue of 59-year-old female bronchial wall. HBD-3 IMH, ×200.
e hig est ex ressi f - s o s r i cartil f ro c i l ll ( -
erate) ( able 2, Figure 3). A few to moderate HBD-4 expres ion was detected in alveolar
epitheliu and alveolar macrophages (Table 2, Figure 3). Occasional expression of HBD-4
was detected in connective tissue, glands and bronchial epithelium (Table 2, Figure 3).
Table 2. l ti ber of HBD-4-positive structures in the healthy lung structures: cartilage,
connective tissue, glands, bronchial epithelium, alveolar macrophages and alveolar epithelium.
Nr Age
HBD-4
C CT G BE AE AM
1 18 +/++ 0 0/+ + 0 0
2 19 ++ + ++ ++ 0 0
3 19 +/++ 0 0/+ 0/+ + +
4 25 ++/+++ ++ 0/+ 0/+ +++ ++
5 27 ++ 0/+ 0 0 +/++ 0/+
6 29 ++ + 0/+ 0 ++ +++
7 33 +/++ 0/+ 0 0 ++ ++
8 35 +/++ 0 0 0 +/+ +
9 38 ++ + 0/+ 0/+ ++ ++
10 45 0/+ + 0 0/+ + +++
11 55 +/++ 0/+ 0 0 +/++ ++
12 56 ++ 0/+ 0/+ 0/+ +/++ ++
13 59 ++ 0 0 0 0/+ 0/+
14 74 ++ 0/+ 0/+ 0 +/++ +
15 86 + 0/+ 0/+ 0 + 0/+
Common ++ 0/+ 0/+ 0/+ +/++ +/++
Abbreviations: C, cartilage; CT, connective tissue, G, glands; BE, bronchial epithelium; AE, alveolar epithe-
lium; AM, alveolar macrophages; HBD-4, human β defensin 4; 0—no positive structures in the visual field;
0/+—occasional positive structures in the visual field; +—few positive structures; +/++—few to moderate num-
ber of positive structures in the visual field; ++—moderate number of positive structures in the visual field;
++/+++—moderate to numerous positive structures in the visual field; +++—numerous positive structures with
the visual field.
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Figure 3. Immunohistochemical micrograph of occasional to few numbers of HBD-4 positive cells 
in connective tissue, cartilage and alveolar epithelium, but not in the bronchial epithelium of 74-
year-old female. HBD-4 IMH, ×200. 
The highest expression of IL-17A was observed in cartilage, where its expression fluc-
tuated from moderate to numerous positive structures (Table 3, Figure 4a,b). A moderate 
number of IL-17A positive structures was detected in bronchial epithelium, alveolar epi-
thelium and macrophages (Table 3, Figures 5a and 6). A few IL-17A immunoreactive cells 
were detected in glands, but an occasional number of positive structures was detected in 
connective tissue (Table 3, Figure 5b). 
Figure 3. I unohistochemical micrograph of occasional to few numbers of HBD-4 positive cells in
connective tissue, cartilage and alveolar epithelium, but not in the bronchial epithelium of 74-year-old
female. HBD-4 IMH, ×200.
The highest expression of IL-17A was observed in cartilage, where its expression
fluctuated fro moderate to numerous positive structures (Table 3, Figure 4a,b). A moder-
ate number of IL-17A positive structures was detected in bronchial epithelium, alveolar
epithelium and macrophages (Table 3, Figures 5a and 6). A few IL-17A immunoreactive
cells were detected in glands, but an occasional number of positive structures was detected
in connective tissue (Table 3, Figure 5b).
Table 3. Relative number of cathelicidine and IL-17A-positive structures in the healthy lung structures: cartilage, connective
tissue, glands, bronchial epithelium, alveolar macrophages and alveolar epithelium.
Nr Age
LL-37 IL-17A
C CT G BE AE AM C CT G BE AE AM
1 18 ++ + + +/++ 0 0 +++ 0/+ +/++ +/++ 0 0
2 19 ++/+++ + + ++ 0 0 +++ + ++ ++/+++ 0 0
3 19 ++ 0/+ 0 + ++v ++ ++/+++ + + + +/++ ++
4 25 ++ 0/+ 0/+ 0 ++ ++/+++ ++ 0 + 0 ++ ++
5 27 ++ + + +/++ ++ +/++ +++ + + ++ ++ ++
6 29 ++ 0/+ + + ++ ++ +++ 0 + + ++v ++v
7 33 ++ 0/+ + 0 ++/+++ ++ ++/+++ 0/+ + 0 ++/+++ ++
8 35 +/++ + 0/+ 0 ++ ++ ++v 0/+ 0/+ 0 ++v +++
9 38 +/++ 0/+ 0/+ +/++ +/++ +/++ ++ 0 + ++ ++v ++
10 45 ++ 0 + ++ ++v ++ ++/+++ 0/+ 0/+ ++ ++v ++v
11 55 ++v + 0/+ 0 ++ ++ ++ + + ++ ++/+++ ++
12 56 + 0/+ 0/+ +/++ ++ +++ ++ 0/+ 0/+ ++ ++ +++
13 59 + 0/+ 0/+ 0 +/++ ++ ++/+++ 0/+ +/++ 0 ++v ++
14 74 ++ + + +/++ ++v ++v ++ + 0/+ ++ ++v 0
15 86 ++ 0/+ 0/+ +/++ ++ + +++ 0 0/+ 0 ++ ++v
Common ++ + + +/++ ++ ++ ++/+++ 0/+ + ++ ++ ++
Abbreviations: C, cartilage; CT, connective tissue, G, glands; BE, bronchial epithelium; AE, alveolar epithelium; AM, alveolar macrophages;
LL-37, cathelicidine; IL-17A, interleukin 17A; 0—no positive structures in the visual field; 0/+—occasional positive structures in the visual
field; +—few positive structures; +/++—few to moderate number of positive structures in the visual field; ++—moderate number of
positive structures in the visual field; ++/+++—moderate to numerous positive structures in the visual field; +++—numerous positive
structures with the visual field.
A moderate number of cathelicidine-positive structures was detected in bronchial
cartilage, alveolar epithelium and alveolar macrophages (Table 3, Figures 7a and 8). LL-37
was present in a few to moderate immunoreactive cells in bronchial epithelium (Table 3,
Figure 9). Connective tissue and glands demonstrated only a few positive structures
(Table 3, Figure 7b).




Figure 4. Immunohistochemical micrographs in lung tissue samples. (a) Note moderate number of IL-17A immunoreac-
tive cells in the alveolar epithelium and numerous alveolar macrophages of 56-year-old male. IL-17A IMH, ×200; (b) a few 
IL-17A positive structures are observed in glands of 25-year-old male. IL-17A IMH, ×250. 
 
Figure 5. Immunohistochemical micrographs in lung tissue samples. (a) Numerous IL-17A positive cells in cartilage of 19-
year-old male. IL-17A IMH, ×100; (b) moderate IL-17A positive structures in cartilage and none in connective tissue of 25-
year-old male. IL-17A IMH, ×100. 
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Figure 6. Immunohistochemical micrograph in lung tissue samples. Moderate number of IL-17A 
positive epitheliocytes and occasional number of positive connective tissue cells in 45-year-old 
male. IL-17A IMH, ×400. 
Table 3. Relative number of cathelicidine and IL-17A-positive structures in the healthy lung structures: cartilage, connec-
tive tissue, glands, bronchial epithelium, alveolar macrophages and alveolar epithelium. 
Nr Age 
LL-37 IL-17A 
C CT G BE AE AM C CT G BE AE AM 
1 18 ++ + + +/++ 0 0 +++ 0/+ +/++ +/++ 0 0 
2 19 ++/+++ + + ++ 0 0 +++ + ++ ++/+++ 0 0 
3 19 ++ 0/+ 0 + ++v ++ ++/+++ + + + +/++ ++ 
4 25 ++ 0/+ 0/+ 0 ++ ++/+++ ++ 0 + 0 ++ ++ 
5 27 ++ + + +/++ ++ +/++ +++ + + ++ ++ ++ 
6 29 ++ 0/+ + + ++ ++ +++ 0 + + ++v ++v 
7 33 ++ 0/+ + 0 ++/+++ ++ ++/+++ 0/+ + 0 ++/+++ ++ 
8 35 +/++ + 0/+ 0 ++ ++ ++v 0/+ 0/+ 0 ++v +++ 
9 38 +/++ 0/+ 0/+ +/++ +/++ +/++ ++ 0 + ++ ++v ++ 
10 45 ++ 0 + ++ ++v ++ ++/+++ 0/+ 0/+ ++ ++v ++v 
11 55 ++v + 0/+ 0 ++ ++ ++ + + ++ ++/+++ ++ 
12 56 + 0/+ 0/+ +/++ ++ +++ ++ 0/+ 0/+ ++ ++ +++ 
13 59 + 0/+ 0/+ 0 +/++ ++ ++/+++ 0/+ +/++ 0 ++v ++ 
14 74 ++ + + +/++ ++v ++v ++ + 0/+ ++ ++v 0 
15 86 ++ 0/+ 0/+ +/++ ++ + +++ 0 0/+ 0 ++ ++v 
 Common ++ + + +/++ ++ ++ ++/+++ 0/+ + ++ ++ ++ 
Abbreviations: C, cartilage; CT, connective tissue, G, glands; BE, bronchial epithelium; AE, alveolar epithelium; AM, alve-
olar macrophages; LL-37, cathelicidine; IL-17A, interleukin 17A; 0—no positive structures in the visual field; 0/+—occa-
sional positive structures in the visual field; +—few positive structures; +/++—few to moderate number of positive struc-
tures in the visual field; ++—moderate number of positive structures in the visual field; ++/+++—moderate to numerous 
positive structures in the visual field; +++—numerous positive structures with the visual field.  
A moderate number of cathelicidine-positive structures was detected in bronchial 
cartilage, alveolar epithelium and alveolar macrophages (Table 3, Figures 7a and 8). LL-
37 was present in a few to moderate immunoreactive cells in bronchial epithelium (Table 
3, Figure 9). Connective tissue and glands demonstrated only a few positive structures 
(Table 3, Figure 7b). 
Figure 6. Immunohistochemical micrograph in lung tissue samples. Moderate number of IL-17A
positive epitheliocytes and occasional number of positive connective tissue cells in 45-year-old male.
IL-17A IMH, ×400.




Figure 7. Immunohistochemical micrographs in lung tissue samples. (a) Few to moderate LL-37 immunoreactive cells in 
the alveolar epithelium and moderate to numerous LL-37 immunoreactive alveolar macrophages of 56-year-old male. LL-
37 IMH, X200; (b) A few to moderate LL-37 positive structures in glands of 19-year-old male. LL-37 IMH, ×200. 
 
Figure 8. Note a few LL-37 positive epitheliocytes and occasional cathelicidine positive connective 
tissue cells of 56-year-old male. LL-37 IMH, ×250. 
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tissue cells of 56-year-old male. LL-37 IMH, ×250.




Figure 9. Immunohistochemical micrographs in lung tissue samples. (a) Note numerous LL-37 immunoreactive cells in 
cartilage of 19-year-old male. LL-37 IMH, X100; (b) A few LL-37 positive structures in cartilage of 19-year-old male. LL-37 
IMH, ×100. 
3.3. Statistical Analysis 
A statistically significant difference was found between HBD-4 and HBD-2 (p = 0.008) 
(Figure 10a), HBD-3 and HBD-2 (p = 0.006) (Figure 10b), HBD-3 and IL-17A (p = 0.005) 
(Figure 10c), HBD-4 and IL-17A (p = 0.004) (Figure 10d), IL-17A and LL-37 (p = 0.002) (Fig-
ure 10e) in cartilage. Furthermore, a statistical significance in bronchial epithelium was 
found between HBD-4 and HBD-3 (p = 0.038) (Figure 11a), HBD-2 and LL-37 (p = 0.014) 
(Figure 11b), HBD-2 and IL-17A (p = 0.009) (Figure 11c), HBD-4 and LL-37 (p = 0.009) (Fig-
ure 11d), HBD-4 and IL-17A (p = 0.006) (Figure 11e). 
Figure 9. Immunohistochemic l micrographs in lung tissue samples. (a) Note n m rous LL-37
immunoreactive cells in cartilage of 19-year-old male. LL-37 IMH, X100; (b) A few LL-37 positive
structures in cartilage of 19-year-old male. LL-37 IMH, ×100.
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3.3. Statistical Analysis
A statistically significant difference was found between HBD-4 and HBD-2 (p = 0.008)
(Figure 10a), HBD-3 and HBD-2 (p = 0.006) (Figure 10b), HBD-3 and IL-17A (p = 0.005)
(Figure 10c), HBD-4 and IL-17A (p = 0.004) (Figure 10d), IL-17A and LL-37 (p = 0.002)
(Figure 10e) in cartilage. Furthermore, a statistical significance in bronchial epithelium was
found between HBD-4 and HBD-3 (p = 0.038) (Figure 11a), HBD-2 and LL-37 (p = 0.014)
(Figure 11b), HBD-2 and IL-17A (p = 0.009) (Figure 11c), HBD-4 and LL-37 (p = 0.009)
(Figure 11d), HBD-4 and IL-17A (p = 0.006) (Figure 11e).




Figure 10. Wilcoxon test revealing statistically significant difference between the relative numbers of different factors in 
cartilage. (a) A statistically significant difference between HBD-2 and HBD-4 in cartilage. (b) A statistically significant 
difference between HBD-2 and HBD-3 in cartilage. (c) A statistically significant difference between HBD-3 and IL-17A in 
cartilage. (d) A statistically significant difference between IL-17A and HBD-4 in cartilage. (e) A statistically significant 
difference between IL-17A and LL-37 in cartilage. C, cartilage; HBD-2, human β defensin 2; HBD-3, human β defensin 3; 
HBD-4, human β defensin 4; LL-37, cathelicidine; IL-17A, interleukin 17A; o—outlier data—indicates a higher or lower 
relative number of positive cells which lie more than 1.5 but less than 3.0 times the interquartile range below the first 
quartile or above the third quartile. 
Figure 10. Wilcoxon test revealing statistically significant difference between the relative numbers of different factors in
cartilage. (a) A statistically significant difference betwee HBD-2 and HBD-4 in cartilag . (b) A statistically significant
difference between HBD-2 and HBD-3 in cartilage. (c) A statistically significant difference between HBD-3 and IL-17A in
cartilage. (d) A statistically significant difference between IL-17A and HBD-4 in cartilage. (e) A statistically significant
difference between IL-17A and LL-37 in cartilage. C, cartilage; HBD-2, human β defensin 2; HBD-3, human β defensin 3;
HBD-4, human β defensin 4; LL-37, cathelicidine; IL-17A, interleukin 17A; o—outlier data—indicates a higher or lower
relative number of positive cells which lie more than 1.5 but less than 3.0 times the interquartile range below the first quartile
or above the third quartile.
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4 in bronchial epithelium. (e) A statistically significant difference between HBD-4 and IL-17A in bronchial epithelium.  
BE, bronchial epithelium; HBD-2, human β defensin 2; HBD-3, human β defensin 3; HBD-4, human β defensin 4; LL-37, 
cathelicidine; IL-17A, interleukin 17A; o—outlier data—indicates a higher or lower number of relative positive cells which 
lie more than 1.5 but less than 3.0 times the interquartile range below the first quartile or above the third quartile; *—
extreme outlier data—indicates a higher or lower number of relative positive cells which lie more than 3.0 times the inter-
quartile range below the first quartile or above the third quartile. 
A statistically significant difference was found between HBD-4 and HBD-3 (p = 0.015) 
(Figure 12a), HBD-4 and IL-17A (p = 0.003) (Figure 12b) in glands. Moreover, a statistically 
significant difference in alveolar epithelium was observed between HBD-4 and LL-37 (p = 
0.043) (Figure 13a), HBD-3 and IL-17A (p = 0.034) (Figure 13b), HBD-2 and IL-17A (p = 
0.032) (Figure 13c), HBD-4 and IL-17A (p = 0.026) (Figure 13d). HBD-3 and IL-17A (p = 
Figure 11. Wilcoxon test revealing statistically significant difference t t e relative numbers of different factors
in bronchial epithelium. (a) A statistically significant difference between HBD-4 and HBD-3 in bronchial epithelium.
(b) A statistically significant difference between HBD-2 and LL-37 in bronchial epithelium. (c) A statistically significant
difference between HBD-2 and IL-17A in bronchial epithelium. (d) A statistically significant difference between LL-37 and
HBD-4 in bronchial epithelium. (e) A statistically significant difference between HBD-4 and IL-17A in bronchial epithelium.
BE, bronch al epithelium; HBD-2, human β defensin 2; HBD-3, human β defensin 3; HBD-4, human β defensin 4; LL-37,
cathelicidine; IL-17A, interl ukin 17A; o—outlier data—indicates a higher or lower numb r of relative positive cells which
lie more than 1.5 but less than 3.0 times the interquartile range below the first quartile or above the third quartile; *—extreme
outlier data—indicates a higher or lower number of relative positive cells which lie more than 3.0 times the interquartile
range below the first quartile or above the third quartile.
A statistically significant difference was found between HBD-4 and HBD-3 (p = 0.015)
(Figure 12a), HBD-4 and IL-17A (p = 0.003) (Figure 12b) in glands. Moreover, a statis-
tically significant difference in alveolar epithelium was observed between HBD-4 and
LL-37 (p = 0.043) (Figure 13a), HBD-3 and IL-17A (p = 0.034) (Figure 13b), HBD-2 and
IL-17A (p = 0.032) (Figure 13c), HBD-4 and IL-17A (p = 0.026) (Figure 13d). HBD-3 and
IL-17A (p = 0.048) (Figure 14a), HBD-3 and LL-37 (p = 0.019) (Figure 14b) demonstrated
a statistically significant difference in alveolar macrophages.
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alveolar epithelium. (a) A statistically significant difference between LL-37 and HBD-4 in alveolar epithelium. (b) A sta-
tistically significant difference between IL-17A and HBD-3 in alveolar epithelium. (c) A statistically significant difference 
between IL-17A and HBD-2 in alveolar epithelium. (d) A statistically significant difference between IL-17A and HBD-4 in 
alveolar epithelium. AE, alveolar epithelium; HBD-2, human β defensin 2; HBD-3, human β defensin 3; HBD-4, human β 
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Figure 12. Wilcoxon test revealing statistically significant difference between the relative numbers of different factors
in glands. (a) A statistically significant difference between HBD-4 and HBD-3 in glands. (b) A statistically significant
difference between HBD-2 and LL-37 in glands. G, glands; HBD-3, human β defensin 3; HBD-4, human β defensin 4;
IL-17A, interleukin 17A; o—outlier data—indicates a higher or lower number of relative positive cells which lie more than
1.5 but less than 3.0 times the interquartile range below the first quartile or above the thi d quartile.
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Figure 13. Wilcoxon test revealing statistically significant difference between the relative numbers of different factors in alve-
olar epithelium. (a) A statistically significant difference between LL-37 and HBD-4 in alveolar epithelium. (b) A statistically
significant difference between IL-17A and HBD-3 in alveolar epithelium. (c) A statistically significant difference between
IL-17A and HBD-2 in alveolar epithelium. (d) A statistically significant difference between IL-17A and HBD-4 in alveolar
epith lium. AE, alveolar epithelium; HBD-2, human β defen in 2; HBD-3, human β defensin 3; HBD-4, human β defensin 4;
LL-37, cathelicidine; IL-17A, interleukin 17A; o—outlier data—indicates a higher or lower umber of relative positive cells
which li more than 1.5 but less than 3.0 times the interquartile range below the fir t quartile or above the third quartile;
*—extreme outlier data—indicates a higher or lower number of relative positive cells which lie more than 3.0 times the
interquartile range below the first quartile or above the third quartile.
A correlation analysis of the normal lung tissue demonstrated very strong positive
correlation between HBD-3 in alveolar epithelium and HBD-3 in alveolar macrophages
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(ρ = 0.911, p < 0.001), HBD-2 and HBD-3 in alveolar epithelium (ρ = 0.845, p < 0.001), HBD-2
in alveolar epithelium and HBD-3 in alveolar macrophages (ρ = 0.838, p < 0.001) (Table 4).
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A correlation analysis of the normal lung tissue demonstrated very strong positive 
correlation between HBD-3 in alveolar epithelium and HBD-3 in alveolar macrophages (ρ 
= 0.911, p < 0.001), HBD-2 and HBD-3 in alveolar epithelium (ρ = 0.845, p < 0.001), HBD-2 
in alveolar epithelium and HBD-3 in alveolar macrophages (ρ = 0.838, p < 0.001) (Table 4). 
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HBD3 in glands HBD-4 in bronchial epithelium 0.729 0.002 
HBD-2 in alveolar epithelium HBD-4 in alveolar macrophages 0.707 0.003 
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HBD-4 in alveolar macrophages HBD-4 in alveolar epithelium 0.692 0.004 
HBD-3 in bronchial epithelium HBD-4 in bronchial epithelium 0.685 0.005 
LL-37 in alveolar epithelium IL-17A in alveolar epithelium 0.681 0.005 
HBD-2 in cartilage HBD-3 in cartilage 0.674 0.006 
IL-17A in alveolar epithelium HBD-3 in alveolar epithelium 0.670 0.006 
IL-17A in alveolar epithelium HBD-2 in alveolar epithelium 0.659 0.008 
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IL-17A in alveolar epithelium HBD-3 in alveolar macrophages 0.645 0.009 
LL-37 in bronchial epithelium HBD-3 in glands 0.640 0.010 
LL-37 in alveolar epithelium HBD-3 in alveolar macrophages 0.639 0.010 
LL-37 in bronchial epithelium HBD-2 in bronchial epithelium 0.630 0.012 
IL-17A in alveolar epithelium HBD-4 in alveolar epithelium 0.628 0.012 
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Figure 14. Wilcoxon test revealing statistically signifi i ference between the relative numbers of dif erent factors
in alveolar macrophages. (a) statistically significant difference between IL-17A and HBD-3 in alve lar macrophages.
(b) A statistically significant difference between HBD-3 and LL-37 in alveolar macrophages. AM, alveolar macrophages;
HBD-3, human β defensin 3; LL-37, cathelicidine; IL-17A, interleukin 17A; o—outlier data—indicates a higher or lower
number of relative positive cells which lie more than 1.5 but less t an 3.0 times the interquartile range below the first quartile
or above the third quartile; *—extreme outlier data—indicates higher or low r number of relative positive cells which lie
more than 3.0 times the interquartile range below the first quartile or above the third quartile.
Table 4. Spearman’s rank correlation coefficient revealed correlations between the relative numbers of different factors in
healthy lung tissue.
Strength of
Correlation Marker 1 Marker 2 Rho (ρ) p-Value
Very strong positive
correlation
HBD-3 in alveolar epithelium HBD-3 in alveolar macrophages 0.911 <0.001
HBD-2 in alveolar epithelium HBD-3 in alveolar epithelium 0.845 <0.001
HBD-2 in alveolar epithelium HBD-3 in alveolar macroph g s 0.838 <0.001
Strong positive
correlation
HBD-2 in bronchial epithelium HBD-4 in bronchial epithelium 0.781 0.001
HBD-3 in glands HBD-3 in bronchial epithelium 0.733 .002
HBD3 in glands HBD-4 in bronchial epithelium 0.729 0.002
HBD-2 in alveolar epithelium HBD-4 in alveolar macrophages 0.707 0.003
LL-37 in bronchial epithelium IL-17A in bronchial epithelium 0.706 .003
IL-17A in glands HBD-2 in cartilage 0.705 0.003
HBD-4 in alveolar macrophages HBD-4 in alveolar epithelium 0.692 0.004
HBD-3 in bronchial epithelium HBD-4 in bronchial epithelium 0.685 0.005
LL-37 in alveolar epithelium IL-17A in alveolar epithelium 0.681 0.005
HBD-2 in cartilage HBD-3 in cartilag 0.674 .006
IL-17A in alveolar epithelium HBD-3 in alveolar epithelium 0.670 0.006
IL-17A in alveolar epithelium HBD-2 in alveolar epithelium 0.659 0.008
LL-37 in alveolar macrophages HBD-4 in alveolar macr phages 0.658 .008
IL-17A in alveolar epithelium HBD-3 in alveolar macrophages 0.645 0.009
LL-37 in bronchial epithelium HBD-3 in glands 0.640 0.010
LL-37 in alveolar epithelium HBD-3 in alveolar macrophages 0.639 0.010
LL-37 in bronchial epithelium HBD-2 in bronchial epithelium 0.630 0.012
IL-17A in alveolar epithelium HBD-4 in alveolar epithelium 0.628 0.012
Abbreviations: HBD-2, human β defensin 2; HBD-3, human β defensin 3; HBD-4, human β defensin 4; LL-37, cathelicidine; IL-17A,
interleukin 17A.
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Strong positive correlation was found between HBD-2 and HBD-4 in bronchial epithe-
lium (ρ = 0.781, p = 0.001), HBD-3 in glands and bronchial epithelium (ρ = 0.733, p = 0.002),
HBD-3 in glands and HBD-4 in bronchial epithelium (ρ = 0.729. p = 0.002), HBD-2 in alveo-
lar epithelium and HBD-4 in alveolar macrophages (ρ = 0.707, p = 0.003), LL-37 and IL-17A
in bronchial epithelium (ρ = 0.706, p = 0.003), IL-17A in glands and HBD-2 in cartilage
(ρ = 0.705, p = 0.003), HBD-4 in alveolar epithelium and alveolar macrophages (ρ = 0.692,
p = 0.004), HBD-3 and HBD-4 in bronchial epithelium (ρ = 0.685, p = 0.005), LL-37 and
IL-17A in alveolar epithelium (ρ = 0.681, p = 0.005) (Table 4). In addition, strong positive
correlation was detected between HBD-2 and HBD-3 in cartilage (ρ = 0.674, p = 0.006),
IL17A and HBD-3 in alveolar epithelium (ρ = 0.670, p = 0.006), IL-17A and HBD-2 in alveo-
lar epithelium (ρ = 0.659, p = 0.008), LL-37 and HBD-4 in alveolar macrophages (ρ = 0.658,
p = 0.008), IL-17A in alveolar epithelium and HBD-3 in alveolar macrophages (ρ = 0.645,
p = 0.009), LL-37 in bronchial epithelium and HBD-3 in glands (ρ = 0.640, p = 0.010), LL-37
in alveolar epithelium and HBD-3 in alveolar macrophages (ρ = 0.639, p = 0.010), LL-37
and HBD-2 in bronchial epithelium (ρ = 0.630, p = 0.012), IL-17A and HBD-4 in alveolar
epithelium (ρ = 0.628, p = 0.012) (Table 4).
4. Discussion
Our results generally covered healthy lungs, particularly the cartilage, alveolar epithe-
lium and the alveolar macrophages as the main places for the antimicrobial proteins and
IL-17A synthesis as the local defence factors here were observed in moderate number of
cells in all the patients.
AMPs and IL-17A production is carried out mainly by epithelial and immune cells.
Relevant studies have demonstrated dominant AMPs and IL-17A expression by alveolar ep-
ithelium and alveolar macrophages during early infection, and showed necessity for lower
pathogen agent concentration to stimulate expression of these factors in the alveolar epithe-
lium and alveolar macrophages than in other structures of the respiratory system [44–46].
That shows importance of the alveolar epithelium and alveolar macrophages in the innate
immune response of the lungs. An unexpected finding was AMP, especially LL-37 and
IL-17A, high expression in hyaline cartilage of the lungs. Expression of these factors in
cartilage most likely demonstrate plasticity of the structure, its importance in local tissue
defence and its ability in rapid adaptation. Many different factors are involved in the
development, adaptation and regeneration of cartilage, the role of which at first seems
clear. Vascular endothelial growing factor (VEGF) and fibroblast growing factor 18 (FGF18)
are involved in fetal cartilage development and in processes associated with cartilage
damage. Although both factors’ roles in cartilage development are similar, relevant studies
demonstrated VEGF degradational effect; however, in contrast, FGF18 protective and
regeneration stimulating effect on cartilage in osteoarthritis [47–49]. Our knowledge of
cartilage, especially in the respiratory system (tracheal and bronchial cartilages), its secreted
factors and its role in our organism is limited and requires more in-depth research.
According to our data, the bronchial epithelium with relatively indistinct expression
of antimicrobial proteins, and exceptionally expressing the LL-37 and IL-17A in moderate
number of cells, probably indicates this airway epithelial barrier as more plastic under the
direct different influences of the environment.
Expression of LL-37 as an inactive pro-peptide and intracellular collection of factors
occurs not only in immune cells such as neutrophiles and macrophages, but also in ep-
ithelial cells of the respiratory system, especially after vitamin D stimulation [31]. These
reserves of the factor can be easily mobilized with minimal concentration of air containing
exogenous triggers [33]. What is interesting, is the wide spectrum of stimuli which can
provoke LL-37 expression and activation—Gram-positive and Gram-negative bacteria,
viruses, fungi and protozoa. Activated LL-37 induces dose dependent IL-17A production
which in turn provide other antimicrobial peptide gene stabilization and expression [37].
The cooperation of these two mediators provides first line defence against pathogens.
Although HBD-2 is considered as the most highly expressed defensin in respiratory system,
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its expression in the bronchial epithelium is lower than in the alveolar epithelium, and
HBD-2 secretion is induced mainly by Gram-negative bacteria [12]. HBD-3 and HBD-4
expression in the respiratory system is not as high as LL-37 and HBD-2, but their activity
against different pathogens like Gram-positive and Gram-negative bacteria, and HBD-3
lack of sensitivity to salt concentration changes, demonstrate these factors as an additional
protective step in innate immunity [18,20,24]. Based on the above mentioned and our
gathered data, we suggest that the uneven expression of AMPs and IL-17A in the bronchial
epithelium shows a multi-level system of immune defence and plasticity of the epithelial
barrier of the respiratory system against various trigger factors.
Immunohistochemical reaction demonstrated related changes of HBD-3 and HBD-4
expression in different tissues that seemingly are associated with synergistic cooperation of
these two mediators in the lung host defence. This idea is confirmed by the strong posi-
tive correlation between HBD-3 and HBD-4 in glands, bronchial and alveolar epithelium.
Relevant studies showed that HBD-3 is a more potent mediator against Gram-positive
Staphylococcus aureus, but HBD-4 demonstrated its full dominance as AMP against Gram-
negative Pseudomonas aeruginosa [18,24]. HBD-3 and HBD-4 direct antimicrobial activity
is different, and mediators complement each other to provide better protection against
pathogens that invade the respiratory system. According to research of Xuejun Chen et al.,
the involvement of both mediators is important to ensure adequate mast cells mobilization:
HBD-3 demonstrated its dominance in mast cells degranulation and PGD2 generation,
but HBD-4 promoted more enhanced migration of mast cells than HBD-3 [27]. Interaction
of HBD-3 and HBD-4 in mast cells activation and migration shows synergistic involve-
ment of mediators in inflammatory reaction moderation. The above-mentioned leads
to the conclusion that the synergistic co-working of these two mediators provide highly
potent antimicrobial activity in different respiratory system tissues based on the innate
immune response.
HBD-2 secretion in healthy bronchial cartilage of our subjects was statistically sig-
nificant compared with HBD-3 and HBD-4. According to other studies, expression of
HBD-2 was not seen in healthy articular cartilage, but, after tissue stimulation with IL-1β,
IL-6, TNF-α and Pseudomonas aeruginosa, HBD-2 mRNA induction was detected [50,51].
Such opposing activity of the HBD-2 in cartilage can be explained by tissue location and
intensity of different trigger factor influences. Each day our respiratory system filtrates
approximately 11,000 litres of the air which contains macro- and microscopical particles,
including bioaerosols (dead and alive fungi and bacteria, bacterial endotoxins, mycotoxins,
pollen and so on), peeled skin and dust [52]. Bioaerosols induce IL-1β IL-6, TNF-α and
other pro-inflammatory factor production [53,54], which activate HBD-2 mRNA through
different pathways (PI3K, NFkB, MAPK) leading to antimicrobial and anti-inflammatory
reactions and immune system homeostasis.
Interestingly, HBD-2 role in cartilage is not only associated with antimicrobial ac-
tivity and anti-inflammatory effects, but it is also involved in cartilage repair and cell
proliferation. Relevant studies have indicated HBD-2 role as a link between antimicrobial
activity and cartilage remodelling processes by involvement in proliferation and differenti-
ation of chondrocytes [50,55]. This demonstrates multifunctional activity of HBD-2 in the
human organism.
An interesting finding was increased secretion of LL-37 and IL-17A in cartilage, mainly
in the proliferation zone. LL-37 and IL-17A are mainly produced by epitheliocytes and
immune cells and are involved in inflammatory process regulation. Relevant studies
demonstrated LL-37 and IL-17A involvement in some inflammatory processes of joints,
like inflammatory arthritis, where both of these mediators stimulate significant TNFα
secretion and development of chronic inflammation, but immune cells and synovial cells
were the source of LL-37 and IL-17A in inflammatory arthritis, not hyalinocytes [42,56].
Moreover, we have not found any mention of cathelicidine and IL-17A secretion in the
cartilage. As a result, this is the first detection of LL-37 and IL-17A expression in hyaline
cartilage. Both of these mediators are inflammatory process regulators, which shows their
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possible involvement in lung cartilage immune processes, but more detailed research
should be conducted to determine the specific role of IL-17A and LL-37 in hyaline cartilage
of the lungs.
LL-37 and IL-17A have demonstrated interaction with each other, which was shown
in our research by the intercorrelation between LL-37 and IL-17A in the bronchial epithe-
lium, connective tissue and cartilage. Other studies have indicated that LL-37 alone can
selectively regulate inflammation-related processes through the NF-kB signalling path-
way [57]. This regulation proceeds by increased phosphorylation of IkappaB (IkB) kinase
(IKK) and p65 [42]. Meanwhile, IL-17A alone also stimulates proinflammatory processes
through NF-kB and boosts the phosphorylation of p65 and IkB and slightly increases
that of IKK [42,58]. Chakkrapong Kuensaen demonstrated IL-17A early expression after
stimulation with LL-37 and higher gene expression response to combined stimulation with
both mediators than LL-37 alone [42]. As a result, LL-37 activates and cooperates with
IL-17A, leading to inflammation intensification and prolongation long term.
5. Conclusions
Regardless of age, all healthy lung structures, but especially the cartilage, alveolar
epithelium and the alveolar macrophages, are the main locations for the baseline synthe-
sis of antimicrobial proteins and IL-17A, while the bronchial epithelium (as a structure
more sensitive to the influence of environment) produces only indistinct baseline an-
timicrobial protein levels with exception for IL-17A and cathelicidine to be expressed in
numerous cells.
Significant detection of all antimicrobial proteins in healthy lung hard tissue—cartil-
age—shows high functional plasticity of this structure, including significant antimicrobial
activity and participation in local lung protection response.
Interrelated changes between antimicrobial proteins HBD-3, HBD-2, HBD-4, LL-37
and IL17A, but especially between HBD-3 and HBD-4 expression in different tissues,
confirms baseline synergistic cooperation of all these factors in the healthy lung host
defence, regardless of age.
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43. Junga, A.; Pilmane, M.; Ābola, Z.; Volrāts, O. The Distribution of Vascular Endothelial Growth Factor (VEGF), Human Beta-
Defensin-2 (HBD-2), and Hepatocyte Growth Factor (HGF) in Intra-Abdominal Adhesions in Children under One Year of Age.
Sci. World J. 2018, 2018, 5953095. [CrossRef]
44. Rivas-Santiago, B.; Hernandez-Pando, R.; Carranza, C.; Juarez, E.; Contreras, J.L.; Aguilar-Leon, D.; Torres, M.; Sada, E. Expression
of cathelicidin LL-37 during Mycobacterium tuberculosis infection in human alveolar macrophages, monocytes, neutrophils, and
epithelial cells. Infect. Immun. 2008, 76, 935–941. [CrossRef]
45. Mikacenic, C.; Hansen, E.E.; Radella, F.; Gharib, S.A.; Stapleton, R.D.; Wurfel, M.M. Interleukin-17A Is Associated With Alveolar
Inflammation and Poor Outcomes in Acute Respiratory Distress Syndrome. Crit. Care Med. 2016, 44, 496–502. [CrossRef]
[PubMed]
46. Duits, L.A.; Ravensbergen, B.; Rademaker, M.; Hiemstra, P.S.; Nibbering, P.H. Expression of β-defensin 1 and 2 mRNA by human
monocytes, macrophages and dendritic cells. Immunology 2002, 106, 517–525. [CrossRef] [PubMed]
47. Nagao, M.; Hamilton, J.L.; Kc, R.; Berendsen, A.D.; Duan, X.; Cheong, C.W.; Li, X.; Im, H.J.; Olsen, B.R. Vascular endothelial
growth factor in cartilage development and osteoarthritis. Sci. Rep. 2017, 7, 13027. [CrossRef]
48. Davidson, D.; Blanc, A.; Filion, D.; Wang, H.; Plut, P.; Pfeffer, G.; Buschmann, M.D.; Henderson, J.E. Fibroblast growth factor
(FGF) 18 signals through FGF receptor 3 to promote chondrogenesis. J. Biol. Chem. 2005, 280, 20509–20515. [CrossRef]
49. Mori, Y.; Saito, T.; Chang, S.H.; Kobayashi, H.; Ladel, C.H.; Guehring, H.; Chung, U.I.; Kawaguchi, H. Identification of fibroblast
growth factor-18 as a molecule to protect adult articular cartilage by gene expression profiling. J. Biol. Chem. 2014, 289,
10192–10200. [CrossRef] [PubMed]
50. Varoga, D.; Paulsen, F.P.; Kohrs, S.; Grohmann, S.; Lippross, S.; Mentlein, R.; Tillmann, B.N.; Goldring, M.B.; Besch, L.; Pufe, T.
Expression and regulation of human β-defensin-2 in osteoarthritic cartilage. J. Pathol. 2006, 209, 166–173. [CrossRef]
51. Varoga, D.; Pufe, T.; Harder, J.; Meyer-Hoffert, U.; Mentlein, R.; Schröder, J.M.; Petersen, W.J.; Tillmann, B.N.; Proksch, E.;
Goldring, M.B.; et al. Production of endogenous antibiotics in articular cartilage. Arthritis Rheum. 2004, 50, 3526–3534. [CrossRef]
52. Douwes, J.; Thorne, P.; Pearce, N.; Heederik, D. Bioaerosol health effects and exposure assessment: Progress and prospects. Ann.
Occup. Hyg. 2003, 47, 187–200. [CrossRef]
53. Hernandez, M.L.; Mills, K.; Almond, M.; Todoric, K.; Aleman, M.M.; Zhang, H.; Zhou, H.; Peden, D.B. IL-1 receptor antagonist
reduces endotoxin-induced airway inflammation in healthy volunteers. J. Allergy Clin. Immunol. 2015, 135, 379–385. [CrossRef]
54. Thorne, P.S. Inhalation toxicology models of endotoxin-and bioaerosol-induced inflammation. Toxicology 2000, 152, 13–23.
[CrossRef]
Clin. Pract. 2021, 11 746
55. Kraus, D.; Deschner, J.; Jäger, A.; Wenghoefer, M.; Bayer, S.; Jepsen, S.; Allam, J.P.; Novak, N.; Meyer, R.; Winter, J. Human
β-defensins differently affect proliferation, differentiation, and mineralization of osteoblast-like MG63 cells. J. Cell. Physiol. 2011,
227, 994–1003. [CrossRef] [PubMed]
56. Sakkas, L.I.; Zafiriou, E.; Bogdanos, D.P. Mini review: New treatments in psoriatic arthritis. Focus on the IL-23/17 axis. Front.
Pharmacol. 2019, 10, 872. [CrossRef]
57. Mookherjee, N.; Brown, K.L.; Bowdish, D.M.; Doria, S.; Falsafi, R.; Hokamp, K.; Roche, F.M.; Mu, R.; Doho, G.H.; Pistolic, J.; et al.
Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J. Immunol.
2006, 176, 2455–2464. [CrossRef] [PubMed]
58. Zhang, J.; Wang, D.; Wang, L.; Wang, S.; Roden, A.C.; Zhao, H.; Li, X.; Prakash, Y.S.; Matteson, E.L.; Tschumperlin, D.J.; et al.
Profibrotic effect of IL-17A and elevated IL-17RA in idiopathic pulmonary fibrosis and rheumatoid arthritis-associated lung
disease support a direct role for IL-17A/IL-17RA in human fibrotic interstitial lung disease. Am. J. Physiol. Lung Cell. Mol. Physiol.
2019, 316, L487–L497. [CrossRef] [PubMed]
